December 19, 2019
Biogen Japan Managing Director Ajai Sulekh Biogen is aiming to file its resurrected Alzheimer’s drug aducanumab in Japan next year, just as in the US as previously announced, its local executives told reporters on December 18. Discussions with Japanese regulators...read more